A look at PDMPs in PA-what they are doing and how they are helping patients.
As the opioid epidemic intensifies, state-based Prescription Drug Monitoring Programs (PDMPs) are stepping in to help address the issue. At the same time, states are asking providers (and in many cases requiring them) to review PDMPs when they are considering prescribing controlled substances to patients.
Pennsylvania recently joined the growing number of states that mandate provider usage of PDMPs. Its 2014 law, “Achieving Better Care by Monitoring All Prescriptions Program ACT,” provided for the PA PDMP, and legislation went into effect June 30, 2015. Pharmacies began reporting all controlled substances June 24, 2016, and providers
Dean T Perrywere required to begin using the PDMP database August 25, 2016.
At CBI’s Prescription Drug Monitoring Programs conference in Baltimore on February 7, presenter Dean T. Parry, RPh, Associate Vice President, Clinical Informatics, Care Support services, at Geisinger Health System, shared how the 12-hospital integrated system in Pennsylvania and New Jersey is helping providers meet the new requirements.
Related article: Why is Missouri the Last Drug Monitoring Holdout?
Goals of the PA PDMP program include:
To comply with the PDMP requirements, Geisinger providers now must:
Actions taken by Geisinger to prepare providers for the program, according to Parry, included:
Despite the challenges associated with the PDMP, Parry has received some positive feedback from providers. For example, through PDMP reviews, many have identified patients with previously unknown abuse or misuse problems.